The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to

Avy Violari (), Maysseb Masenya, Stephane Blanche, Simon Vanveggel, Veerle Hufkens, Polan Chetty and Magda Opsomer
Additional contact information
Avy Violari: Chris Hani Baragwanath Hospital, University of the Witwatersrand
Maysseb Masenya: Shandukani Research Centre, Wits RHI
Stephane Blanche: Hôpital Necker–Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP) and Faculté de Médecine Paris Descartes
Simon Vanveggel: Janssen Pharmaceutica NV
Veerle Hufkens: Janssen Pharmaceutica NV
Polan Chetty: Janssen Research and Development
Magda Opsomer: Janssen Pharmaceutica NV

Drug Safety, 2021, vol. 44, issue 4, No 6, 439-446

Abstract: Abstract Introduction Darunavir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor boosted with ritonavir (DRV/r) or cobicistat. Objective This study provided continued access to DRV/r and assessed long-term safety in patients aged 3 to

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-01032-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:44:y:2021:i:4:d:10.1007_s40264-020-01032-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-01032-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().